Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The FK506-binding protein (FKBP) F36V mutant is a genetically engineered variant of the human FKBP12 protein, in which the phenylalanine at position 36 is replaced by valine. This mutation creates a unique, hydrophobic specificity pocket within the ligand-binding site of FKBP12, enabling selective binding to synthetic ligands that do not interact with wild-type FKBP12. It is widely used in chemical biology as part of dimerization systems. Synthetic ligands can induce or disrupt dimerization/fusion events involving proteins tagged with this mutant domain, enabling conditional control over signaling pathways or transcriptional activity. Ligand-induced recruitment of E3 ubiquitin ligases via fusion to an F36V-FKBP tag enables rapid degradation of target proteins.
Selective binding to synthetic ligands with "bumped" substituents, enabling conditional protein dimerization or degradation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FK506-binding protein F36V mutant domain (F36V-FKBP12).